Mabtech and Sai Life Sciences Form Strategic Partnership to Expand EYRA Immunology Platform Access in US Market
核心洞察
Mabtech (搜索) and Sai Life Sciences (搜索) have established a strategic collaboration that positions Sai's Boston laboratory as a co-marketed US execution and demonstration hub for the advanced EYRA immunology platform.
The partnership will deliver high-sensitivity multiplex cytokine (搜索) and phenotyping workflows to accelerate immune profiling capabilities for companies developing immuno-oncology (搜索), vaccines, inflammation (搜索), and cellular therapy treatments.
The EYRA platform (搜索) overcomes limitations of traditional flow-based and plate-based systems by enabling simultaneous detection of dozens of analytes in a single run with minimal hands-on time.
Mabtech (搜索), a Swedish life science tools company specializing in advanced immunoassays, and Sai Life Sciences (搜索), a leading integrated Contract Research, Development, and Manufacturing Organization (CRDMO), announced a strategic collaboration on January 28, 2026, that establishes Sai's Boston laboratory as a co-marketed US execution and demonstration hub for the Mabtech EYRA platform (搜索).
Advanced Immunology Services Integration
Under the collaboration, the two companies will jointly deliver advanced immunology assay services, including high-sensitivity multiplex cytokine (搜索) and phenotyping workflows, powered by the EYRA platform (搜索) installed at Sai's Boston discovery site. This initiative is designed to accelerate access to next-generation immune profiling capabilities for biopharma and biotech companies working in immuno-oncology (搜索), vaccines, inflammation (搜索), and cellular therapy.
"We're excited to see EYRA placed at Sai Life Sciences (搜索) and integrated into their US discovery operations," said Kimberlee Parent, Head of US Operations at Mabtech (搜索). "This installation enables Sai to offer EYRA's powerful, no-flow multiplex immunology readouts to their broad customer base, expanding access to high-quality, reproducible immune profiling. Together, Mabtech's assay expertise and Sai's strong discovery and translational capabilities create a compelling new service offering for researchers."
EYRA Platform Capabilities
The EYRA platform (搜索) incorporates intuitive software, automation readiness, and simultaneous detection of dozens of analytes in a single run with minimal hands-on time. Originally developed through a long-term R&D collaboration, EYRA overcomes key limitations of traditional flow-based and plate-based systems, enabling streamlined and scalable immune profiling workflows.
"For our discovery clients, the ability to generate reliable, decision-enabling data early is critical," said Maneesh Pingle, Head of Discovery Services at Sai Life Sciences (搜索). "By establishing our Boston site as a US execution hub for EYRA-enabled immunology workflows, we are strengthening Sai's capability to support complex programs in immunology and immuno-oncology (搜索). This collaboration with Mabtech (搜索) allows us to integrate advanced immune profiling seamlessly into broader discovery and translational strategies—helping teams move from biological hypothesis to confident development decisions faster."
Collaboration Framework
Key elements of the strategic partnership include joint service delivery of EYRA-based immunology panels and custom assays, co-branded demonstrations and pilot programs at Sai Boston, shared thought leadership and case study development, and integrated business development engagement supporting discovery through translational research.
Mabtech (搜索) operates as a Swedish life science tools company delivering high-quality immunoassays, reagents, and instrumentation to support advanced immunology research worldwide. Sai Life Sciences (搜索) functions as a full-service CRDMO working with innovator pharma and biotech companies globally to accelerate the discovery, development, and commercialization of small molecules and emerging modalities, with operations across India, the UK, and the US.